On September 9, 2025, Avidity Biosciences amended its incentive plan to increase stock reserves from 4.5 million to 8 million shares. The company also announced positive data on September 10 from its delpacibart zotadirsen trials, showing significant improvements in muscle function and dystrophin production among participants.